[go: up one dir, main page]

AR070731A1 - Composicion farmaceutica para farmacos poco solubles - Google Patents

Composicion farmaceutica para farmacos poco solubles

Info

Publication number
AR070731A1
AR070731A1 ARP090100726A ARP090100726A AR070731A1 AR 070731 A1 AR070731 A1 AR 070731A1 AR P090100726 A ARP090100726 A AR P090100726A AR P090100726 A ARP090100726 A AR P090100726A AR 070731 A1 AR070731 A1 AR 070731A1
Authority
AR
Argentina
Prior art keywords
dosage form
solid dosage
active pharmaceutical
pharmaceutical ingredient
solid
Prior art date
Application number
ARP090100726A
Other languages
English (en)
Inventor
De Vasconcelos Teofilo Cardoso
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of AR070731A1 publication Critical patent/AR070731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Una forma de dosificacion solida, para la liberacion de un ingrediente farmacéutico activo poco soluble (IFA), comprendiendo la forma de dosificacion solida una dispersion solida, caracterizada porque la dispersion solida comprende un ingrediente farmacéutico activo perteneciente a la Clase II de BCS, un vehículo amorfo y un surfactante, en la que la cantidad de surfactante es de 0,5 a 30% del peso total de la dispersion solida, y en la que al menos el 30% del ingrediente farmacéutico activo está en una forma amorfa. Reivindicacion 2: Una forma de dosificacion solida de acuerdo con la reivindicacion 1, caracterizado porque la forma de dosificacion es para la liberacion rápida del IFA. Reivindicacion 5: Una forma de dosificacion solida de acuerdo con la reivindicacion 1, caracterizado porque la forma de dosificacion es para la liberacion sostenida del IFA. Reivindicacion 7: Una forma de dosificacion solida de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizado porque la forma de dosificacion es una formulacion de cápsula, estando contenida la dispersion solida en una envoltura externa de un material farmacéuticamente aceptable. Reivindicacion 9: Una forma de dosificacion solida de acuerdo con la reivindicacion 8, caracterizado porque la forma de dosificacion es un comprimido. Reivindicacion 25: Una forma de dosificacion solida de acuerdo con la reivindicacion 24, caracterizado porque el ingrediente farmacéutico activo se selecciona de fármacos analgésicos, antipiréticos, antimigranosos, antidepresivos, relajantes musculares, antiepilépticos, anticonvulsivos, antiparkinsonianos, antieméticos, ansiolíticos, fármacos usados en el tratamiento de trastornos afectivos como trastorno bipolar, antipsicoticos y fármacos contra el Alzheimer. Reivindicacion 26: Una forma de dosificacion solida de acuerdo con cualquiera de las reivindicaciones 1 a 23, caracterizado porque el ingrediente farmacéutico activo es un inhibidor de COMT, un inhibidor de FAAH, un inhibidor de dopamina beta-hidroxilasa o un antagonista del canal del sodio. Reivindicacion 45: Una forma de dosificacion solida de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizado porque el ingrediente farmacéutico activo no se disuelve en 250 ml de tampones acuosos con un pH entre 1-7,5.
ARP090100726A 2008-02-28 2009-03-02 Composicion farmaceutica para farmacos poco solubles AR070731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3219008P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
AR070731A1 true AR070731A1 (es) 2010-04-28

Family

ID=40577908

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100726A AR070731A1 (es) 2008-02-28 2009-03-02 Composicion farmaceutica para farmacos poco solubles

Country Status (12)

Country Link
US (1) US20110014282A1 (es)
EP (1) EP2259777A2 (es)
JP (1) JP2011513301A (es)
KR (1) KR20100126452A (es)
CN (1) CN101959504A (es)
AR (1) AR070731A1 (es)
AU (1) AU2009217865A1 (es)
BR (1) BRPI0908340A2 (es)
CA (1) CA2715802A1 (es)
IL (1) IL207512A0 (es)
MX (1) MX2010009043A (es)
WO (1) WO2009108077A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL169855A (en) * 2005-07-25 2014-05-28 Elta Systems Ltd A system and method for locating a receiver location
ES2545178T3 (es) 2005-07-26 2015-09-09 Bial-Portela & Ca, S.A. Derivados de nitrocatecol como inhibidores de la COMT
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
CL2009000628A1 (es) * 2008-03-17 2010-04-09 Bial Portela & Companhia S A Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
JP5499703B2 (ja) * 2009-12-28 2014-05-21 ライオン株式会社 イブプロフェン含有製剤
CN102781424B (zh) 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
US9044394B2 (en) * 2010-10-18 2015-06-02 PruGen IP Holdings, Inc. Bioavailability enhancement delivery composition
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CN102716493B (zh) * 2011-03-31 2014-05-28 天津药物研究院 含无定型态阿戈美拉汀的共聚物、其制备方法、其药物组合物及用途
CN102178642A (zh) * 2011-04-29 2011-09-14 苏州大学 一种替米沙坦固体分散体及其制备方法
KR20130106456A (ko) * 2011-04-29 2013-09-30 한국유나이티드제약 주식회사 약물 방출제어용 조성물
US20150011525A1 (en) 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
KR101332223B1 (ko) * 2011-09-19 2013-11-25 충남대학교산학협력단 프란루카스트 나노 고체 분산체의 제조방법 및 이로써 제조된 나노 고체 분산체
ES2606148T3 (es) * 2011-11-01 2017-03-22 Inopharm Limited Composición de disgregación oral de agentes antihistamínicos
CN102641245B (zh) * 2011-11-02 2014-02-26 中国科学院过程工程研究所 一种装载难溶性药物的壳聚糖-壳聚糖衍生物纳米球、制备方法及其作为口服制剂的应用
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
WO2013117963A1 (en) * 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
TW201343201A (zh) * 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
IN2012DE00674A (es) * 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
KR101280005B1 (ko) * 2012-03-16 2013-07-05 유우영 무수무복계물질
CN102988297A (zh) * 2012-12-21 2013-03-27 无锡泓兴生物医药科技有限公司 罗氟司特固体分散体及含有其的药物组合物
AU2014212109B2 (en) * 2013-02-01 2018-05-31 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
CN103360357B (zh) * 2013-08-07 2015-07-22 中国药科大学 辛伐他丁格列齐特共无定型物
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CA2976811C (en) 2015-03-10 2023-06-27 Shionogi Inc. Solid dispersions of ospemifene
KR20170039347A (ko) 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
AU2017262586B2 (en) * 2016-05-09 2023-04-13 AustinPx, LLC Improved drug formulations
CN105853383B (zh) * 2016-05-23 2019-04-30 苏州中化药品工业有限公司 一种治疗糖尿病性神经病变的药物组合物及其制备方法
CN106727382A (zh) * 2016-12-27 2017-05-31 中国药科大学 一种卡维地洛过饱和自微乳分散片及其制备方法
CN106727388A (zh) * 2017-03-27 2017-05-31 华益药业科技(安徽)有限公司 乙酰唑胺片及其制备方法
CN107088186A (zh) * 2017-04-28 2017-08-25 华南理工大学 一种含叶黄素的固体分散体及其制备方法
CN113164394B (zh) * 2018-12-13 2023-06-23 广东东阳光药业有限公司 一种维拉佐酮固体分散体及其制备方法
EP4125923A1 (en) * 2020-04-01 2023-02-08 Board of Regents, The University of Texas System Pharmaceutical compositions of niclosamide
WO2022008515A1 (en) * 2020-07-07 2022-01-13 Atxa Therapeutics Limited Thromboxane receptor antagonist formulations
GB202011709D0 (en) * 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN112535665A (zh) * 2020-12-14 2021-03-23 宁夏医科大学 一种格列吡嗪固体分散体及制备方法和包含其的格列吡嗪固体分散体片及制备方法
CN114699373B (zh) * 2022-03-30 2023-03-17 山东新时代药业有限公司 一种甲氧氯普胺固体分散体及其制备方法
CN114767633B (zh) * 2022-04-07 2023-03-31 郑州大学第一附属医院 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂
CN114831951B (zh) * 2022-04-25 2023-10-03 扬子江药业集团广州海瑞药业有限公司 依折麦布片剂及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532176A (en) * 1922-07-21 1925-04-07 Daimler Motorengesellschaft Motor vehicle of any kind
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4386668A (en) * 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US6206110B1 (en) * 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
WO2000017175A1 (en) * 1998-09-18 2000-03-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
IT1320176B1 (it) * 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN100364531C (zh) * 2002-12-18 2008-01-30 西托维亚公司 3,5－二取代－[1,2,4]－二唑及类似物和其用途
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
KR20050031847A (ko) * 2003-09-30 2005-04-06 삼성전자주식회사 복수의 재생경로를 가지는 동영상 데이터에 대한 텍스트기반의 자막 정보가 기록된 저장 매체, 재생 장치 및 그재생 방법
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP2007535551A (ja) * 2004-04-28 2007-12-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物
US9504658B2 (en) * 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
US20080051441A1 (en) * 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
KR20080000622A (ko) * 2005-04-26 2008-01-02 뉴로서치 에이/에스 신규한 옥사디아졸 유도체 및 이의 의학적 용도
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006132914A2 (en) * 2005-06-03 2006-12-14 Abbott Laboratories Cyclobutyl amine derivatives
FR2889525A1 (fr) * 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
JP4738419B2 (ja) * 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
KR20080022452A (ko) * 2006-09-06 2008-03-11 삼성전자주식회사 Ｐｏｐ 패키지 및 그의 제조 방법
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
DK2481410T3 (en) * 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen

Also Published As

Publication number Publication date
AU2009217865A1 (en) 2009-09-03
EP2259777A2 (en) 2010-12-15
MX2010009043A (es) 2010-10-25
IL207512A0 (en) 2010-12-30
CA2715802A1 (en) 2009-09-03
WO2009108077A2 (en) 2009-09-03
JP2011513301A (ja) 2011-04-28
KR20100126452A (ko) 2010-12-01
BRPI0908340A2 (pt) 2018-12-26
CN101959504A (zh) 2011-01-26
US20110014282A1 (en) 2011-01-20
WO2009108077A3 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
PE20120654A1 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
NZ602510A (en) Treatment of lupus nephritis using laquinimod
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
UA116334C2 (uk) Тверді форми дозування бендамустину
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
UA102120C2 (ru) Пероральная форма дозирования бендамустина
TN2015000135A1 (en) Modified release formulations for oprozomib
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2014119985A3 (es) Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel

Legal Events

Date Code Title Description
FB Suspension of granting procedure